GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NovMetaPharma Co Ltd (XKRX:229500) » Definitions » Pretax Margin %

NovMetaPharma Co (XKRX:229500) Pretax Margin % : -12,368.20% (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is NovMetaPharma Co Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. NovMetaPharma Co's Pre-Tax Income for the six months ended in Dec. 2024 was ₩-5,604.65 Mil. NovMetaPharma Co's Revenue for the six months ended in Dec. 2024 was ₩45.32 Mil. Therefore, NovMetaPharma Co's pretax margin for the quarter that ended in Dec. 2024 was -12,368.20%.

The historical rank and industry rank for NovMetaPharma Co's Pretax Margin % or its related term are showing as below:

XKRX:229500' s Pretax Margin % Range Over the Past 10 Years
Min: -90644.61   Med: -9428.52   Max: -77.72
Current: -12368.2


XKRX:229500's Pretax Margin % is ranked worse than
99.07% of 972 companies
in the Drug Manufacturers industry
Industry Median: 6.145 vs XKRX:229500: -12368.20

NovMetaPharma Co Pretax Margin % Historical Data

The historical data trend for NovMetaPharma Co's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovMetaPharma Co Pretax Margin % Chart

NovMetaPharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15,179.87 -10,091.88 -19,512.12 -90,644.61 -12,368.20

NovMetaPharma Co Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -15,179.87 -10,091.88 -19,512.12 -90,644.61 -12,368.20

Competitive Comparison of NovMetaPharma Co's Pretax Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, NovMetaPharma Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovMetaPharma Co's Pretax Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NovMetaPharma Co's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where NovMetaPharma Co's Pretax Margin % falls into.


;
;

NovMetaPharma Co Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

NovMetaPharma Co's Pretax Margin for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-5604.65/45.315
=-12,368.20 %

NovMetaPharma Co's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-5604.65/45.315
=-12,368.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NovMetaPharma Co  (XKRX:229500) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


NovMetaPharma Co Pretax Margin % Related Terms

Thank you for viewing the detailed overview of NovMetaPharma Co's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


NovMetaPharma Co Business Description

Traded in Other Exchanges
N/A
Address
727 13, Gangnam-gu, Seoul eonju layer, Seoul, KOR
NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer's disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.

NovMetaPharma Co Headlines

No Headlines